Kochujang, a Fermented Soybean-based Red Pepper Paste, Decreases Visceral Fat and Improves Blood Lipid Profiles in Overweight Adults
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01532375|
Recruitment Status : Completed
First Posted : February 14, 2012
Last Update Posted : February 14, 2012
|Condition or disease||Intervention/treatment||Phase|
|Overweight||Dietary Supplement: Kochujang Dietary Supplement: placebo||Phase 2|
The aim of this study was to evaluate the efficacy of KCJ supplementation on anthropometric parameters, visceral fat/subcutaneous fat, and blood lipid profiles in overweight subjects.
Sixty overweight subjects with BMI >25 kg/m2 and waist-hip-ratio (WHR) ≥ 0.90 for men and ≥ 0.85 for women were randomly assigned to either KCJ supplement (n=30, 32 g/day) or placebo (n=30, 32 g/day) group for 12 weeks.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Kochujang Decreases Visceral Fat and Improves Lipids Profiles|
|Study Start Date :||October 2009|
|Actual Primary Completion Date :||March 2010|
|Actual Study Completion Date :||March 2010|
Dietary Supplement: Kochujang
Kochujang (32g/day) for 12weeks.
|Placebo Comparator: placebo(32g)||
Dietary Supplement: placebo
placebo(32g/day) for 12weeks
- Visceral fat [ Time Frame: after 12 weeks of consumption ]
- Body Mass Index [ Time Frame: after 12 weeks of consumption ]
- Subcutaneous fat [ Time Frame: after 12weeks ]
- Triglyceride [ Time Frame: after 12week of consumption ]
- Atherosclerosis index [ Time Frame: after 12weeks of consumption ]
- Apolipoprotein [ Time Frame: after 12weeks of consumption ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01532375
|Study Chair:||Soo-Wan Chae, Ph.D, MD||Chonbuk National University Hospital|